IP Library Granted Patent US 10,076,533
Granted Patent B2
US 10,076,533 · App. 15/809,400 · Granted Sep 18, 2018

Acyclic nucleoside phosphonate diesters

Inventors: Karl Y. Hostetler (Del Mar, CA); James R. Beadle (San Diego, CA); Nadejda Valiaeva (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/675C07F9/6561C07F9/65121C07F9/65616C07F9/65583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,076,533
App. No.
15/809,400
Granted
Sep 18, 2018
Kind
B2
Abstract

The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.

Claims (22)

1. A method of treating cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the compound is topically administered as a topical formulation.

4. The method of claim 3 , wherein the topical formulation is a cream.

5. The method of claim 3 , wherein the topical formulation is a gel.

6. The method of claim 1 for treating cervical intraepithelial neoplasia.

7. The method of claim 6 , wherein the subject is a human.

8. The method of claim 6 , wherein the compound is topically administered as a topical formulation.

9. The method of claim 8 , wherein the topical formulation is a cream.

10. The method of claim 8 , wherein the topical formulation is a gel.

11. The method of claim 1 for treating anal intraepithelial neoplasia.

12. The method of claim 11 , wherein the subject is a human.

13. The method of claim 11 , wherein the compound is topically administered as a topical formulation.

14. The method of claim 13 , wherein the topical formulation is a cream.

15. The method of claim 13 , wherein the topical formulation is a gel.

16. The method of claim 1 for treating vulvar intraepithelial neoplasia.

17. The method of claim 16 , wherein the subject is a human.

18. The method of claim 16 , wherein the compound is topically administered as a topical formulation.

19. The method of claim 18 , wherein the topical formulation is a cream.

20. The method of claim 18 , wherein the topical formulation is a gel.

21. The method of claim 1 , wherein the cervical intraepithelial neoplasia, the anal intraepithelial neoplasia, or the vulvar intraepithelial neoplasia is caused by a human papilloma virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: HOSTETLER, KARL Y.; BEADLE, JAMES R.; VALIAEVA, NADEJDA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 045623/0308 →
Continuity (7)
Continuation 15617841 · Jun 8, 2017
Continuation 15179209 · Jun 10, 2016
Continuation 14874027 · Oct 2, 2015
Continuation 14463908 · Aug 20, 2014
Continuation 14211235 · Mar 14, 2014
Provisional Application 61793993 · Mar 15, 2013
Related Publication 20180071323A1 · Mar 15, 2018